{
    "name": "clobetasol",
    "comment": "Rx",
    "other_names": [
        "Cormax",
        "Clobex",
        "Clobex Spray",
        "Cormax Ointment",
        "Cormax Scalp Application",
        "Impoyz",
        "Olux",
        "Olux-E",
        "Clobex Shampoo",
        "Clodan Kit",
        "Clodan Shampoo"
    ],
    "classes": [
        "Corticosteroids",
        "Topical"
    ],
    "source": "https://reference.medscape.com/drug/clobex-clobetasol-topical-343516",
    "pregnancy": {
        "common": [
            "Safety data on clobetasol in pregnant woman is not available",
            "Published data report a significantly increased risk of low birthweight with the use of greater than 300 grams of potent or very potent topical corticosteroid during a pregnancy",
            "Advise pregnant women of the potential risk to a fetus and to use clobetasol on the smallest area of skin and for the shortest duration possible",
            "In animal reproduction studies, increased malformations (eg, cleft palate and skeletal abnormalities), were observed after SC administration of clobetasol to pregnant mice and rabbits"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "No information is available regarding the presence of clobetasol in breast milk or its effects on the breastfed infant or on milk production",
            "Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects",
            "Unknown whether topical administration of clobetasol could result in sufficient systemic absorption to produce detectable quantities in human milk",
            "To minimize potential exposure to the breastfed infant via breast milk, use clobetasol on the smallest area of skin and for the shortest duration possible while breastfeeding",
            "Advise breastfeeding women to avoid applying clobetasol directly to the nipple and areola to prevent direct infant exposure"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Viral, fungal, or tubercular skin lesions",
                "Hypersensitivity",
                "Ophthalmic use"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Chronic topical corticosteroid therapy may interfere with growth and development in children",
                "May cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, especially in younger children or patients receiving high doses for prolonged periods",
                "Use lower potency in children; may absorb proportionally larger amounts after topical application and may cause systemic effects; treatment of children <12 years not recommended; prolonged use may affect growth velocity (routinely monitor growth in pediatric patient); Clobex lotion, Clobex spray, Clobex shampoo, Clodan shampoo not recommended for use in patients <17 years",
                "Allergic contact dermatitis reported with use; diagnosed by failure to heal rather than clinical exacerbation",
                "Kaposi sarcoma reported with prolonged corticosteroid treatment; consider discontinuing therapy if it occurs",
                "Percutaneous absorption of corticosteroids may cause manifestations of Cushing syndrome",
                "Topical corticosteroids may increase the risks of glaucoma and posterior subcapsular cataract; glaucoma and cataracts reported in postmarketing; avoid contact with eyes; advise patients to report any visual symptoms",
                "Foam dosage form is flammable; avoid fire, flame, or smoking during and immediately following application",
                "Local effects, including perioral dermatitis, acneiform eruptions, folliculitis, hypopigmentation, skin atrophy, miliaria, secondary infection, and telangiectasia may occur; effects may be reversible",
                "Concomitant skin infections may be present or develop during therapy; discontinue if dermatological infection persists after antimicrobial therapy"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Skin atrophy",
            "percent": "4.2"
        },
        {
            "name": "Telangiectasia",
            "percent": "3.2"
        },
        {
            "name": "Discomfort skin",
            "percent": "1.3"
        },
        {
            "name": "Dry skin",
            "percent": "1"
        }
    ]
}